Lynx1 Capital Management LP Bellus Health Inc. Transaction History

Lynx1 Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$7.14 - $8.53 $1.62 Million - $1.94 Million	-227,254 Reduced 20.77%	866,646 $6.24 Million
Q4 2022 Feb 14, 2023	SELL	$8.22 - $10.76 $10.6 Million - $13.9 Million	-1,288,227 Reduced 54.08%	1,093,900 $8.99 Million
Q3 2022 Nov 14, 2022	SELL	$8.95 - $12.0 $4.02 Million - $5.39 Million	-449,461 Reduced 15.87%	2,382,127 $25.2 Million
Q2 2022 Aug 15, 2022	SELL	$6.46 - $10.02 $129,200 - $200,400	-20,000 Reduced 0.7%	2,831,588 $26.2 Million
Q1 2022 May 16, 2022	BUY	$5.56 - $7.99 $4.72 Million - $6.78 Million	848,474 Added 42.36%	2,851,588 $19.6 Million
Q4 2021 Feb 14, 2022	BUY	$5.26 - $8.3 $10.5 Million - $16.6 Million	2,003,114 New	2,003,114 $16.1 Million

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Lynx1 Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Lynx1 Capital Management LP with notifications on news.